Ongoing clinical trials are Phase 3 trials of GVAX immunotherapy for prostate cancer.

Cell Genesys is on the development and commercialization of novel biological therapies for patients with cancer. The company is currently pursuing two clinical stage product platforms – GVAX cancer immunotherapies and oncolytic virus therapies. Ongoing clinical trials are Phase 3 trials of GVAX immunotherapy for prostate cancer, Phase 2 trials. GVAX immunotherapy for pancreatic cancer and leukemia , and a Phase 1 trial of CG0070 oncolytic virus therapy for bladder cancer Cell Genesys its former subsidiary hold any interest in its former subsidiary, Ceregene, to develop gene therapies for neurodegenerative diseases.

We look not 100 % resistance, but the parasite is much less susceptible to artemisinin than we are used to, when used with other drugs in combination, we can still cure malaria, but it takes a few days longer, ‘Arjen Dondorp led the study, the Telegraph reports (Leach.. This information was of globalhealth.org courtesy of the Henry J. Kaiser Family Foundation you can view the entire Kaiser Daily Global Health Policy Report, search the archives and sign up for e-mail delivery of global health.Our studies show that tocotrienols bear the potential for the preventive or treatment of metabolic syndrome These research is further evidence that natural tocotrienol will no a far stronger form of vitamin E unique health related advantage divided by alpha-tocopherol,. Most common form of vitamin E is, said Mr. Arthur Ling, CEO Davos Life Science in Singapore, a company specializes in the research & development and production of tocotrienols.. Increased triglyceride levels one of the risk factors for identifying metabolic syndrome, which, to an increase in risk of cardiovascular diseases By inducing the expression associated.